Quick Answer
Tonix Pharmaceuticals Holding Corp. reported Total Revenue of $13.11 million for fiscal year 2025.
Tonix Pharmaceuticals Holding Corp. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $13.11M +29.8% |
$10.09M +29.9% |
$7.77M | — | — | — |
| Revenue (ASC 606) | $13.11M +29.8% |
$10.09M +29.9% |
$7.77M | — | — | — |
| Net Income | -$124.02M +4.6% |
-$130.04M -11.5% |
-$116.66M -5.8% |
-$110.22M -19.4% |
-$92.29M -82.9% |
-$50.46M -76.3% |
| Diluted EPS | -$14.57 +91.7% |
-$176.60 +98.8% |
-$14720.25 -73464.5% |
-$20.01 -147.0% |
-$8.10 | — |
| Total Assets | $277.17M +70.2% |
$162.89M +5.5% |
$154.46M -31.6% |
$225.69M -6.3% |
$240.90M +145.4% |
$98.18M +574.4% |
| Cash and Equivalents | $207.64M +110.2% |
$98.78M +295.9% |
$24.95M -79.2% |
$120.23M -32.7% |
$178.66M +131.8% |
$77.07M +585.1% |
| Long-Term Debt | — | $4.67M -28.9% |
$6.56M | — | — | — |
| Stockholders Equity | $245.15M +75.7% |
$139.56M +32.3% |
$105.53M -49.1% |
$207.18M -5.3% |
$218.72M +149.5% |
$87.65M +830.7% |
| R&D Expense | $44.49M +11.3% |
$39.97M -53.9% |
$86.66M +5.8% |
$81.88M +18.9% |
$68.84M +90.4% |
$36.16M +98.8% |
| Operating Income | -$125.70M +8.0% |
-$136.70M -15.5% |
-$118.38M -5.6% |
-$112.09M -21.4% |
-$92.31M -82.8% |
-$50.51M -75.2% |
| Shares Outstanding | 559.04M +485.1% |
95.54M +456479.4% |
20,926 -99.8% |
12.37M -20.9% |
15.64M -92.4% |
206.01M +1210.7% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $3.29M | +16.6% | +64.7% |
| Revenue (ASC 606) | September 30, 2025 | $3.29M | +16.6% | +64.7% |
| Net Income | September 30, 2025 | -$32.01M | -125.2% | -13.2% |
| Diluted EPS | September 30, 2025 | -$3.59 | +84.2% | +7.0% |
| Total Assets | September 30, 2025 | $252.44M | +165.8% | +34.7% |
| Cash and Equivalents | September 30, 2025 | $190.06M | +573.2% | +51.6% |
| Long-Term Debt | December 31, 2024 | $4.67M | -28.9% | -9.8% |
| Stockholders Equity | September 30, 2025 | $231.14M | +211.5% | +37.6% |
| R&D Expense | September 30, 2025 | $9.29M | +1.9% | -14.1% |
| Operating Income | September 30, 2025 | -$33.07M | -112.6% | -16.9% |
| Shares Outstanding | September 30, 2025 | 10.17M | -93.5% | +34.7% |
- Tonix Pharmaceuticals Holding Corp. reported Total Revenue of $13.11 million for fiscal year 2025.
- Tonix Pharmaceuticals Holding Corp. showed an increase of +29.8% in Total Revenue compared to the prior fiscal year.
- Tonix Pharmaceuticals Holding Corp. reported Revenue (ASC 606) of $13.11 million for fiscal year 2025.
- Tonix Pharmaceuticals Holding Corp. showed an increase of +29.8% in Revenue (ASC 606) compared to the prior fiscal year.
- Tonix Pharmaceuticals Holding Corp. reported Net Income of -$124.02 million for fiscal year 2025.
- Tonix Pharmaceuticals Holding Corp. showed an increase of +4.6% in Net Income compared to the prior fiscal year.
- Tonix Pharmaceuticals Holding Corp. reported Diluted EPS of $14.57 per share (loss) for fiscal year 2025.
- Tonix Pharmaceuticals Holding Corp. showed an increase of +91.7% in Diluted EPS compared to the prior fiscal year.
- Tonix Pharmaceuticals Holding Corp. reported Total Assets of $277.17 million for fiscal year 2025.
- Tonix Pharmaceuticals Holding Corp. showed an increase of +70.2% in Total Assets compared to the prior fiscal year.
- Tonix Pharmaceuticals Holding Corp. reported Cash and Equivalents of $207.64 million for fiscal year 2025.
- Tonix Pharmaceuticals Holding Corp. showed an increase of +110.2% in Cash and Equivalents compared to the prior fiscal year.
- Tonix Pharmaceuticals Holding Corp. reported Long-Term Debt of $4.67 million for fiscal year 2024.
- Tonix Pharmaceuticals Holding Corp. showed a decrease of -28.9% in Long-Term Debt compared to the prior fiscal year.
- Tonix Pharmaceuticals Holding Corp. reported Stockholders Equity of $245.15 million for fiscal year 2025.
- Tonix Pharmaceuticals Holding Corp. showed an increase of +75.7% in Stockholders Equity compared to the prior fiscal year.
- Tonix Pharmaceuticals Holding Corp. reported R&D Expense of $44.49 million for fiscal year 2025.
- Tonix Pharmaceuticals Holding Corp. showed an increase of +11.3% in R&D Expense compared to the prior fiscal year.
- Tonix Pharmaceuticals Holding Corp. reported Operating Income of -$125.70 million for fiscal year 2025.
- Tonix Pharmaceuticals Holding Corp. showed an increase of +8.0% in Operating Income compared to the prior fiscal year.
- Tonix Pharmaceuticals Holding Corp. reported Shares Outstanding of 12.79 million shares for fiscal year 2025.
- Tonix Pharmaceuticals Holding Corp. showed a decrease of -97.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: